Vanessa Coiteux is a partner in the Corporate Group. Her practice focuses on securities, public and private mergers & acquisitions and corporate financing. She frequently advises issuers and underwriters in connection with public and private offerings in Canada and abroad, as well as TSX-listed securities issuers on regulatory compliance, corporate governance and continuous disclosure requirements matters. Vanessa specializes in cybersecurity and advises public and private companies on legal, ethical and governance issues. She advises clients on a wide range of privacy, data security and information management matters, including information security breach responses, compliance and disclosure, and provides advice on best cybersecurity business practices. Vanessa works with businesses from various industry sectors including the engineering, communications, computer science, pharmaceutical, manufacturing and retail industries. She is a member of the firm's Associates Committee and the Montreal office’s Premises Committee.
Valeant Pharmaceuticals International, Inc. (Valeant) acquired Salix Pharmaceuticals, Ltd. (Salix) for US$173.00 per share in cash, or a total enterprise value of approximately US$15.8 billion. The transaction closed on April 1, 2015. To partially finance the acquisition, Valeant completed equity and bond offerings, which closed on March 27, 2015. In its equity offer, Valeant issued 7,286,482 shares at a price of US$199.00 per share, for aggregate gross proceeds of approximately US$1.45 billion.